Xceleron, the global leader in ultra-sensitive analysis techniques for the acceleration of drug development, announced today an agreement with Resverlogix Corp., Canada (TSX: RVX) to conduct a Phase 0 human microdose study on their lead molecule(s) for raising ‘good’ cholesterol levels to reduce plaque in the fight against cardiovascular disease.
